selecting an ar inhibitor for m0 crpc treatment
Published 5 years ago • 27 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
2:55
implications for treating with ar inhibitors in m0 crpc
-
4:02
managing m0 crpc patients on ar inhibitors
-
7:12
ep. 8: selecting optimal ar-targeted therapy for nmcrpc
-
53:41
emerging treatment of m0 crpc: update on the aua/suo guidelines
-
8:30
ar-targeted therapies in crpc
-
40:09
adt as foundational therapy: consistent t suppression, goals, monitoring, and delaying time to crpc
-
1:34
an oral ar/ar-v7 protac for the treatment with castration-resistant prostate cancer (crpc)
-
1:58:24
the changing face of advanced prostate cancer (2024)
-
2:01:46
chemotherapy and immunotherapy for the urologist and advanced practice provider (2024)
-
1:32:31
unlocking the power of modern therapeutic regimens for prostate cancer
-
2:35
the aramis trial in m0 crpc
-
28:19
targeting ar in castration resistant prostate cancer
-
27:43
more arrows in our quiver - targeting the adaptive molecular landscape of advanced prostate cancer
-
3:13
treatment options in metastatic prostate cancer
-
51:32
castration-resistant prostate cancer (crpc) guideline amendment
-
44:10
advances in adt part ii: a guide for urologists
-
3:38
the nccn and aua guidelines for treating nmcrpc
-
3:56
bone-targeted therapy for prostate cancer: radium-223
-
36:32
chair’s take on innovation in prostate cancer: thoughts on new evidence
-
1:06:58
immuno-oncology: a focus on prostate cancer
-
1:25:04
the prostate cancer therapeutic landscape: expert guidance on treatment sequencing and selection
-
53:40
setting up a clinic in the community setting | the role of chemotherapy treatment